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Since the mtroduetion of thrombolyric therapy for acute 
myocatdiil infarction, tbe incidence of coronary artery reocclu- 
sion has been intensively studied. Also, the prediction and diag- 
nosis of reocclusion uv angiographic and clinical variables, as well 
its invasive and pha-macologic prevention, have gained much 
attention. 
By angiograpbii definition, reocclusion requires three angio- 
graphic observations: one with au occluded artery, one with a 
reperfused artery and a third for the assessment of subsequent 
ocdusion (true reocclusion). Since the introduction of early 
intravenous reperfustoo therapy, most studies use only two angio- 
grams: one with a patent and one wttb a oonpatent infarct-related 
artrry. A search for all poblished reocclusion studies reveakd 61 
studies (6,061 patients) with at least two angiograms. The median 
tbne iuterval betweec the first angkgram after thromholysis and 
tbe second was 16 days (range 0.1 to 363). Reocclusion was 
observed in 666 (II%) of 6,061 cases. Interestingly, the 28 true 
reocclusion studies showed an incidence of reocclusion of 16 f 
18% (mean + SD), and the 33 studii witb only two angiogmms 
10 2 8% (p = 0.04), suggesting tbat proven initial occlusion of the 
infar&related artery is a risk factor for reocclusion after success- 
Besides bleeding, a major drawback of thrombolytic therapy 
for acute my xardial infarction is the increased incidence of 
recurrent ischemia. probably a result of coronary artery reoc- 
elusion (1). This review deals with the pathologir, clinical, 
anpiographic, therapeutic and prognostic aspects ol coronary 
reocclusion after thromholytic therapy for acute myocardial 
infarction, as well as the- strategies to prevent it. 
Definition of Reocclusion 
The angiographic definition of coronary reocclusion is 
literally that it occurs after I) angiographically proven initial 
occlusion of the infarct-related vessel, 2) angiographically 
prov’en suhseyuent successful coronary recanaliLation, and 3) 
ful thrc abolysis. The other predictors for reocclusion are proha- 
bly severity of residual stenosis of the infarct-related artery after 
thmmbolysis and perhaps the flow state after lysis. Reocclusion is 
most frequently seen in the early weeks after tbmmbolysis. The 
clinkal course in patients witb reocclusion is more complkated 
than in those without this complication. Left ventricular contrac- 
tile reeovety after tbmmbolysts is hampered by reocclusion. 
Routine invasive strategies have not been pmven effective 
against reocciusion. In tbe prevention of reocclusion, both anti- 
platelet and antithmmbin strategies have been tested, including 
birudin and birulog, but the safety of tbese agents in thmmholysis 
is still questionable. 
Thus, reocclusion aRer thmmbolysis is an early pbenomenon 
and is more frequent after pmven initial occlusion of the iafarct- 
related artery. Reocclusion can be predicted by angiograpby after 
tbmmholysis. E&cause reocclusion is detrimental, strategies to 
prevent it should be developed and carried out after tbrombolytic 
therapy for acute myocardial infarction as soon as they am 
deemed safe. 
(J Am Coil Cardiol19%;27:766-73) 
angiogrdphicahy proven subsequent occlusion of the infarct- 
related vessel. Although angiography is still the reference 
standard for defining reocclusion, its snapshot characteristic 
makes it almost useless in ciinical practice. Clinical signs of 
reperfusion and reocclusion are better guidelines, hut they lack 
sensitivity and specificity. Interestingly, in patients with chest 
pain and ST segment elevation, angiographic “spontaneous” 
reperfusion is seen m 18% to 20% cf cases (2,3). Since the 
introduction of early intravenous thrombolysis, angiography is 
mostly performed after initial treatment. Loss of coronary 
patency between two angiographic observations is usually 
called reocclusion. Because of these reasons, single angio- 
graphic observations showing an occluded infarct-related ar- 
tery after thrombolysis can hardly represent reocclusion, al- 
though sometimes clinicians erroneously call lack of patency 
reocclusion. 
The angiographic classification of patency is important to 
note. Two grading systems have been used: the European 
Coopcrativc Study Group (4) and the Thromboiysis in Myo- 
cardial Infarction (TIMI) flow grade classitication (2). Cur- 
rently the TIMI ROW grade classification is most widely used, 
and recently it was shown thai insufficient flow, like TIMI flow 
grade 2, is clinically almost identical to TIMI flow grade 0 to I 
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(5.6). With this in r.dnd, reocclusion in the most clinically used 
way means the evolution of TIMI flow grade 3 to absent or low 
clinical flow states (TIM1 flow grade 0 to 2). The large 
combined outcome and angiographic Global Utilization of 
Stleptokinase and t-PA for Occluded Coronary Arteries 
(GUSTO) study yielded insight intq the clinical consequences 
of the several flow states in reperfusion therapy for acute 
myocardial infarction (6). 
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Pathogenesis of Reocclusion 
The pathologic and angiographic observations with throm- 
bolytic therapy have firmly established the role of thrombosis 
in the pathogenesis of acute myocardial infarction. Plaque 
rupture probably causes activation of blood platelets and the 
coagulation cascade, resulting in total thrombotic occlusion of 
a coronary artery. Depending on the area at risk, collateral 
blood flow and the duration of occlusion, the resulting infarct 
will be large or small with little sequelae or with deleterious 
consequences to the patient. Reperfusion therapy is aimed at 
early restoration of blood flow by dissolving or removing 
thrombotic material at the site of the coronary lesion. Because 
the nidus of coro,laty thrombus usually is not removed, 
rethrombosis can easily occur. Because thrombosis and throm- 
bolysis probably represent a subtle balance, reestablishment of 
the thrombotic state may lead to coronary rethrombosis. 
Remarkably, plasminogen activation with exogenous com- 
pounds has the paradoxic effect of activating both platelets and 
thrombin in the acute phase (7-10). Also, incomplete lysis of 
thrombus (11) and plaque welling after thrombolysis (12) may 
be stimuli for rethrombosis. 
The natural history of residual stenosis after thrombolysis 
shows decremental stenosis severity in the majority of patients, 
suggesting ongoing thrombus resolution and plaque repair 
(13). Platelets cannot only be activated by reexposure to the 
damaged vessel, but also by high shear rates (14). After 
thrombolysis a high grade residual stenosis might activate 
platelets by this mechanism. Experimental studies have shown 
that fibrin-rich thrombus may be replaced by platelet-rich 
thrombus that may be highly resistant to lysis (7). However, 
other processes like inflammation and tissue proliferation 
caused by growth factors cannot be excluded, although they 
have not been studied i;l the setting of reocclusion. 
Reocclusion is probably a time-dependent process. How- 
ever, some vessels show total obstruction early after thrombo- 
lytic therapy and are patent when studied later. Therefore, it 
seems likely that prothrombotic and antithrombotic processes 
continue long after thrombolytic therapy vessel wall repair is 
finished. 
Incidence of Reocclusion 
The incidence of rc+zclusion has been intensively studied 
since the introduction of thrombolytic therapy for acute myo- 
cardial infarction. Through EMBASE a search for reocclusion 
studies was done using the key words reocclusion and fhrom- 
bdytk therapy. Between 1980 and 1994,60 studies with at least 
one follow-up angiogram after angiographical;y successful 
thrombolytic therapy have been published. They included 
6,061 patients, of whom 666 ( I1 %) sustained reoceiusion of the 
infarct-related artery. The median time between the first 
postthrombolysis angiogram and the follow-up angiogram was 
16 days (range 0.1 to 365). The postthrombolysis angiogram 
showed an “open” infarct-related artery or “successful” reper- 
fusion and the follow-up angiogiam an “occluded” artery. 
Studies with three angiograms (one with an occluded artery, 
one with a reperfused artery and a third for the assesment of 
reocclusion) are true reoczlusion studies. The 2E true reocclu- 
sion studies (I ,037 patients) show an incidence of reocclusion 
of 16 2 10% (mean 2 SD). The 33 studies (5,024 patients) 
with only two angiograms (one with an open artery and a 
second for the assessment of reocclusion) report a reocchtsion 
incidence of 10 2 8% (p = 0.04 vs. true reocclusion studies). 
This indicates that angiographically proven initial occlusion of 
the infarct-related artery is a risk factor for ieocclusion. Two 
of the studies with three angiograms have specifically analyzed 
the difference in reocclusion after angiographically proven 
initial occlusion and angiographically proven initial patency. 
Serruys et al. (15) showed reocclusion of 2 (6%) of 36 initially 
open vessels compared with 19 (21%) of Sl initially occluded 
vessels (p < 0.05). For TIMI-I (2), these figures were 2 (5%) of 
40 and 19 (21%) of 91 (p < 0.05). 
Because of the snapshot characteristic of the angiographic 
approach, otheer diagnostic criteria (see later) are eagerly 
awaited. In the meantime, reocclusion can onIy he detected by 
angiography, with its important limitations, such as cost and 
safety. The time window for the diagnosis of reocclusion is very 
important, The first observation of patency is usuaIly per- 
formed between 60 and 180 min after initiation of thrombolytic 
therapy. Follow-up angiography can be performed as early as 
24 h after the first angiogram. The Thrombolysis and Angio- 
plasty in Myiaidial Infarction (TAMI) trial, the largest study 
reporting OF in-hospital ieocclusion comprised 642 patients, 
demonstrated reocclusion of -9% after successful thrombo- 
lytic therapy and 17% reocclusion after initially failed thiom- 
bolytic therapy followed by coronary angioplasty (16). Another 
reported large study of in-hospital reocclusion was GUSTO 
trial, which showed a low reocclusion rate of -6% (6). 
Reocclusion in the first year after thrombolysis is more fre- 
quent. Probably the large time window between which the 
angiograms are obtained (e.g, the first days of thrombolysis 
followed by angiography at 3 months) forms the explanation 
for the high incidence. Reocclusion diagnosed at 3 months 
might be as high as 18% to 32% (17-19). Data on vessel 
patency I year after thrombolytic therapy revealed about the 
same incidence (20). 
To study reocclusion over time, the incidence of ieocclusion 
and the time of the second angiogram are plotted in Figure 1. 
Because reocclusion occurs in a minority of patients treated 
with thrombolysis, only the larger studies were taken into 
account. A cutoff point of 75 patients was chosen. Table 1 
summarizes the 20 studits fulfilling these criteria (2,5,16,18, 
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Pttre 1. Incidence of reocclusion after thmmbolpis in the published 
studies with >75 patients. The x axis represents the time between the 
initiation of thrombolytic therapy and the time of follow-up angiogra- 
pb 
20-33). Figure I clearly shows that rcocclusion is most fre- 
quent in the first week after thrombolysis and its incidence 
levels off in the ensuing months. The incidence of reocclusion 
after thromboiytic therapy increases with the time window of 
observation. The snapshot approach is probably the cause of 
this phenomenon. In contrast, it is quite possible that vessels 
may reocclude intermittently, which is not diagnosed by the 
follow-up angiogram. 
About 25% of patients treated with thrombolytic therapy 
for acute myocardial irfarction fail to achieve reperfusion, 
leaving only 75%’ of successfully treated patients. It is clear 
from the GUSTO trial that early complete vessel patency with 
TIM1 flow grade 3 is only observed in -50% of patients 
undergoing thrombolytic therapy. Approximately 30% of pa- 
tients will experience reocclusion in the subsequent months, 
leaving much less than 50% of patients with successful sus- 
tained full repcrfusion. Thus, only a minority of patients will 
have full sustained benefit from thrombolytic therapy. 
A 21% incidence of reocclusion after primary angioplasty 
for acute mytrardial infarction was reported recently in the 
Primary Angioplasty Myoca:dial Infarction (PAMI) trial in- 
volving a limited number of patients: 33 of 154 patients had 
TIMI flow grade 0 to 2 six months after successful qrimary 
angioplasty (34). The incidence of restenosis was reported to 
be --25X at 3 months (35) and 45%’ at 6 months (34). 
Reocclusion data on thrombolysis in the randomized trials of 
primary angioplasty versus thromboiysis are lacking. 
Noninvasive Indicators of Reocciusion 
Clinical variables have been intensely tested in the predic- 
tion and diagnosis oi coronary reperfusion. In the absence of 
angiography, successful reperfusion is as difficult to diagnose as 
subsequent reocclusion. Relief of chest pain, disappearance of 
ST segment elevation and the occurrence of accelerated 
idioventricular rhythm are all indicators, but no proof of 
successful reperfusion. When, they are combined, they are 
more indicative of reperfusion, and when none oi them are 
present, persistent occlusion is likely. The introduction of 
continuous It-lead ST segment monitoring has made the 
noninvasive diagnosis of fdilcd reperfusion much more sensi- 
tive than the other clinical variables (36). 
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Recurrence of chest pain and ST segment elevation and 
reinfarction are probably indicators of reocclusion. Also, con- 
tinuous l2-lead ST segment monitoring might be a more 
sensitive indicator of reocclusion after coronary thrombolysis 
(37). Other diagnostic tools like thallium-201 or technetium 
sestamihi have not been tested in the diagnosis of reocclusion. 
Prediction of Reocclusion 
After thrombolysis, smoking and the eontimmion of smok- 
ing have been identified as the only independent predietoa of 
reinfarctiun (38), not of reocclusion, and because reinfarction 
is only a part of the spectrum of reoeclusion, no cleareut 
clinical variables can be identified as risk determinants for 
reocclusion. 
Angiographic predictors of reocclusion may include flow 
status, stenosis severity and morphology of the culprit lesion. 
Studies specifically aimeti at identifying the incidence of reoc- 
elusion, not recurrent &hernia (39) are the TAM1 (16), 
TIMI- (33), Aspirin Versus Coumadin Trial (APRICOT) 
(40) and GUSTO (41) studi&s and the study by White et al. 
(20). A poor flow state (TIM1 flow grade 0 or 1) of the 
infarct-related artety at 90 min after thrombolysis initiation 
was a significant predictor of subsequent reocclusi~sn in the 
TAM1 trials and the TIMI- study. However, this finding could 
not be confirmed in the GUSTO angiographtc study (41). In 
the APRICOT study, reoeehrsion was the primary end point in 
284 patients, and only patients with TIM1 flow grade 3 were 
included. All patients with TIM1 flow grade 2 or less were 
regarded as showing reocelusion on the second angiogram. It 
was clearly shown that stenosis severity is an independent risk 
factor (odds ratio 2.3) for the occurrence of reoeclusion. 
Interestingly, a smooth morphology of the culprit lesion is also 
associated with reocclusion. Also, in the trial by White et al. 
(20) and the TIM14 study (33), residual stenosis severity 
proved to be a predictor of reoeelusion in the year after 
successful thrombolysis. 
As stated previously, angiographically proven initial occlu- 
sion of the infarct-related artery seems to be a risk factor for 
subsequent reocclusion. Thus, the risk of reocclusion can 
probably be predicted by early angiographic observation both 
before and after thrombolytic therapy. 
Consequences of Reocclusion 
The presence of both an initially open artery and salvaged 
myocardiun, may determine the clinical manifestations of 
reocclusion. Reocclusion may be associated with recurrent 
angina, reinfarction, pump failure and death. It may also occur 
without symptoms. Symptomless reoeclusion may be assoei- 
ated with the presence of collateral channels protecting the 
salvaged myocardium against renewed damage at the time of 
rcocclusion. In contrast, symptomless reocclusion may also 
indicate a lack of it&tally salvaged myocardium. This question 
has not yet been answered, and no conclusive studies evaluat- 
ing the presence of myocardial viability and consequences of 
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Table 1. Reocclttsion Rates After Successful Thrombolysi* (summary of trials with at least 75 patients) 
First Author or 5 udy Angfographic Thrombofyric Average Rcoeclusion 
Name (ref no., No. of Pts’ Angiogram Time Window Agent rw 
IC (+W) SK 
IC SK 
SK, IPA 
sertuys (15) 
Timmis (21) 
TfM1-1 (2) 
TAMI-I (22) 
Uebis-I (23) 
Uebis-2 (23) 
Anderson ct al. (24) 
PRIMI (3lJ) 
Ohman (16) 
1AMI I-S (26) 
TEAM.2 (25) 
ARMS (28) 
TAMI- (27) 
TAPS-1 (29) 
TAPS-2 (29) 
HART (31) 
APRICOT (18) 
GUSTO (6) 
TIMI-5 (32) 
White (201 
TIMI- (33) 
91 
95 
91 
197 
lo6 
76 
17 
213 
419 
607 
l9u 
102 
157 
339 
339 
98 
24x 
x36 
183 
154 
278 
1st Awe. serial 
2nd 2-m wk 
1st Acute, serial 
2nd IO-24 d 
1st Acute, serial 
2nd 5-2Sd 
1st 90 min 
2nd 7-10 d 
1st Acute, serial 
2nd Id 
1st Acute. serial 
2nd hmo 
1st W min 
2nd <24 h 
1st 45-75 min 
2nd 24-36 h 
1st W min 
2nd 7d 
ISI 90 min 
2nd 7-10 d 
1st %2&l min 
2nd Id 
1st 90 min 
2nd 24 h 
1st 90 min 
2nd 5-10 d 
1st 90 min 
2nd 24-48 h 
1st ‘x) min 
2nd 14-21 d 
1st 7-24 h 
2nd 7d 
1st ~48 h 
2nd 3 mo 
1st 90 min 
2nd 5-7 d 
1st 90 mitt 
2nd 16-36 h 
1st 4wk 
2nd IF 
1st 90 min 
2nd 18-34 h 
tPA 12 
IC SK 6 
IC SK 25 
IC SK. APSAC 
pro-UK 
IV UK, tPA. 
IV UKttPA 
IV UK, IPA. 
IV UK+tPA 
SK. APSAC 2 
APSAC 4 
IV UK, tPA 7 
APSAC, tPA 6 
APSAC. IPA 
tPA 
SK, APSAC 
II 
9 
29 
SK, tPA, 
SK+tPA 
IPA 
h 
4 
25 SK. tPA 
APSAC, tPA 
21 
14 
19 
5 
‘With qiographically succ~~ful thrombolysis and with one or more follow-up an&rams. APRICOT = 
Antith.ombotis in the Prevention of Reocclusion in Coronary Thrombolysis; APSAC = aniqlated plasminogen 
streptokinase activator mmpler; ARMS = APSAC Reocclasion Multicenter Srudy; d = day; GUSTO = Global 
Utilization of Streptokinase and tPA for Occluded Coronary Arteries HART = Heparin-hpirin Reperfusion Trial; IC 
= intracoronmy; IV = intravenous; PRIM1 = Pro-Urokinaw in My-dial Infarction; pro-UK = pm-umtinaae: Pts = 
patient;; ref = reference; SK = streptokinase; TAM1 = Thmmbolysis and Angioplasty in My-dial Infarction: TAPS 
= t-PA APSAC Patency Study; TEAM = Trial of Eminase Versus Alteplase in Myocardial Infarction; TIMI = 
Thrombolysis in Myocardial Infarction; tPA = t&rue-&x plasminogen activator; UK = umkinasz. 
collateral channels after reocclusion are available. Some large ventricular function (42). Apparently, reocclusion is deleteri- 
studies showed that reocclusion precludes left ventricular ous for long-term left ventricular function and indirectly 
contractile recovery (16,20,42), especially in the infarcted indicates that myocardial viability exists after successti~l throm- 
region of the left ventricle. This occurs also in the absence of bolysis. 
clinical reinfarction (41). Reocclusion in the anterior region of Recurrent anginn is a poor indicator of reocclusion. Angina 
the left ventricle has the worst consequences for global left is a symptom notoriously difficult to interpret. Reinfarction 
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Table 2. Randomized, Controlled Trials With Two Angiograms for Prevention of Kcocclubicm With flcpurin Aflrr Successful 
Coronary Thromholysis ------.- -- 
Nu of Rc&u$iun With H~DX~II RetzcluGuo With Control P 
AI’RKOT (IN) 155 23 II (median) 3 mu 24/x1 (WC)’ 24!74(326)t NS 
HART (31) 98 111 h (mean) 7d 7/60(12%)t x38 (5%)$ NS 
- 
‘Patients were not receiving aspirin; warfarin WZB started with heparin: heparin was discontinued when thromboplastin lime was therapeutic. tPatient! were not 
receiving aspirin. SPaGents ‘vere receiving aspirin, Jo mgiday. Abbreviations as in Table 1. 
early after thrombolytic therapy is probably due to reocclusion 
because its incidence is twice as high as that for with control 
treatment (3,43&I). Depending on the definition, the reinfarc- 
tion rate can bc as high as 13% (45). To our knowledge, 3 hard 
correlation between reocclusion and reinfarction ha never 
been made. This correlation is scarcely possible because in the 
search for rcocclusion, one IS forced to use the snapshot 
approach. It is likely that reinfarction is the result of recrclu- 
sion. Because reocclusion impedes recovery of left ventricular 
function, it is understandable that mortality is higher with than 
without reocclusion (16). In the thromboiysis-only arms of the 
TAM1 studies 5 (12.8%) of 39 patients with reocclusion died 
versus 15 (4%) of 380 patients without rcocclusion (p < 0.02). 
Prevention of Reocclusion 
Strategies IO prevent rcocclusion may be invasive or nonin- 
vasive. Invasive strategies consisting of early angiography 
followed by angioplasty have been tested extensively in the 
prevention of reocclusion after successful coronary thrombol- 
ysis (46). The largest study, carried out in the United States, 
prospectively analyzed a routine invasive versus a routine 
conservative strategy after thrombolysis with tissue-type plas- 
minogen activator (t-PA) (47). It was clearly shown that a 
routine invasive strategy does not prevent recurrent ischemia, 
reinfarction or death, nor does it preserve residual left ventric- 
ular function after thrombolytic therapy for acute myoccardidi 
infarction. Also, the long-term efficacy of this ;tratcgy has not 
been proven. Apparently, manipulation by it*lgioplasty of a 
postthrombolytic coronary lesion. which contains or has con- 
tained thrombotic material, exposes the patient to untoward 
effects .Jf angioplaqty. like total occlusion or vessel dissection. 
Another invasive strateg;’ to prevent reocclusion is aortic 
balloon counterpulsation immediately after thrombolysis. In 
one large trial (48), this proved to be effective, but th:sc results 
should be confirmed in another study. 
Noninvasive methods to prevent reocclusion have also been 
evaluated and seem to be partially effective. However, in 
analyzing the data, one should clearly discrimindte between 
early coronary patency and proven coronary reocclusion. For 
the diagnosis of early patency, one needs only one angiogram. 
For the diagnosis of reocclusion, one needs at least two 
angiograms: one with a patent and one with a subsequently 
occluded coronary lesion. 
Heparin has been extensively tested after thrombolysis, 
especially with t-PA. Coronary patency evaluated in the first 
hours or days after thrombolytic therapy with t-PA is better 
with than that without intravenous heparin (31,49,X)). These 
data do not necessarily prove that heparin, when used in 
conjunction with t-PA, actually prevents reocclusion. Random- 
ized, controlled studies on the effect of intravenous heparin in 
the prevention of reocclusion after angiographically proven 
successful coronary thrombolysis are scarce and have a nega- 
tive outcome (Table 2). Intravenous heparin followed by 
warfarin sodium (Coumadin) does not prevent long-term 
reocclusion either (18). Heparin infusion after t-PA for acute 
myocardial infarction is probably necessary during a short time 
and can be discontinued 24 h after thrombolytic therapy (51). 
Heparin therapy is notoriously difficult to monitor, which 
might bc the reasor. for its apparent ineffectiveness in prevent- 
ing reocclusion. Partial activated thromboplastin time is the 
usual measure for heparin anticoaguLtion. There is a correla- 
tion between adequacy of heparinization and coronary patency 
(49X but its relation to reocclusion after successful thrombol- 
ysis has not heen systematically studied. Close monitoring of 
heparin therapy after throrabolysis is mandatory not only for 
patency and possibly reocclusion but also for the prevention of 
bleeding. Partial activated thromboplastin time values >90 s 
after thrombrlysis are correlated with an unacceptable risk of 
cerrbral bleeding (52,53). Hirudin and hirulog, highly specific 
antithrombin agents, stem to bc more effective than heparin in 
the prevcnlion of reocclusion after t-PA (32) or streptokinase 
(SJ) (Table 3). However, patient numbers in these trials are 
small, and although more simple than with heparin, hirudin 
Table 3. Randomized. Heparin-Controlled Trial With Two Angiogranis fur fkvention of Rc()cctusi(ln With Hirudin or [jirulog After 
SuccrQ! !;lronary Thromholysis -- -_- ~--.------ll-------lI-- -___-_-_ 
Irl Aulhor 01 SuJy No uf 
Name (WI no., P& 
Rc~#cluGon With Agent 
I!qr.t 
Reocclusion With Hepdrin 
Iu Angi<*gram 
P 
2nd Ar@gram _I---_--. - _._.. --.-__ Ino. (a) of pn] Ino. j 1”) 01. ptsl Value _____ ___~ 
TIMI-! (3:) lb5 HiruGin ‘XI min lb-3b h l/l05 (1%) 
Lidon (54) 
4/f&(7!;) 0.05 
45 I iilul<%g YO min 5d 
---- 
01.30 (0%) l/15(7%) NS 
Ahhreviaricms aa in ‘T&e I. 
- 
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TaMe 4. Randomized. Controlled Trials With Two Angkgrams for Prevention of Reocclusion With Aspirin After Suce&ut 
Coronary Thrombolyris 
1st Author or Study Name No. of Reocclusion With kplrin 
(ret no.) Pt!. 1st Angiugram 2nd An&gram [no. (96) of pu] 
APRICOT (IX) I67 23 h (median) 3mo u/93 (25%) 
White (2U) 154 4wk t Yr W!J (23%) 
HART (31) 98 18 h (mean) 7d 208 (5%) 
R~~~~cclusion With C&o1 
[no. (%) of puj 
24174 (32%) 
2Oi75 (27%) 
7/60 (12%N 
“ah 
NS 
NS 
NS 
‘Comhinrd with diwridsmole. ZOO me twice a dav. tPatients w^re r%ivine intravenous heparin with a partial activated thromhoplastin time between 1 5 and 20 S. 
Abbreviations as in Take 1. 
also needs close monitoring, because it is associated with more treated. If it occurs early, rethrombolysis is an option, although 
cerebral bleedings than heparin (52,53,55). revascularization seems to be a more definite solution. 
The role of antiplatelet therapy after thrombolytic therapy 
in the prevention of reinfarction has been firmly established 
(43). However, the mechanism by which this benefit is achieved 
is not clear (56). Many believe that antiplatelet therapy 
prevents reocclusion after thrombolysis, but this has never 
been proved. Patency after thrombolysis is better with aspirin 
than without it (57) but this does not prove aspirin prevents 
reocclusion. Placebo-controlled studies with aspirin in success- 
fully thrombolyzed patients with follow-up angiograms are 
scarce. They show that aspirin only tends to prevent reocclu- 
sion (18,20,57) (Table 4). 
Because the reocclusion trials with heparin and aspirin are 
few in number and small in size, large-scale angiographic 
studies are necessary to identify the role of these agents in the 
prevention of reocclusion. However, placebo-controlled stud- 
ies cannot be carried out any more because the place of these 
drugs in the standard thrombolytic strategies for optimal 
patency and reduction of reinfarction has been Armly estab 
lished. 
Primary angioplasty without the use of thrombolysis might 
eliminate factors in the culprit lesion leading to reocclusion. 
However, as stated before, the reocclusion rate after this 
therapy has been reported in only a limited number of patients 
and does not seem to differ from reocrlusion after thrombol- 
ysis, although more data from randomized trials are necessary. 
Currently several antiplatelet and antithrombin strategies 
after thrombolytic therapy are being clinically tested. 
The optimal time for angiography after thrombotytic ther- 
apv for acute myocardial infarction is probably several daya 
before hospital discharge. The patency of the infarct-related 
vessel can be used for risk stratification for either reocclusion 
or further left ventricular functional recovery. Culprit lesion 
severity tends to diminish over time (13) and a not severely 
stenosed infarct-related artery will not reocelude easily (40). 
When the infarct-related vessel is open but severely stenoaed, 
revascularixation seems to be indicated, because these vessels 
tend to reocclude (13,20). If the infarct-related vessel is 
occluded, angioplasty can be carried out to allow left ventric- 
ular contractile recovery (58). Patients with minimal infarction 
in relation to estimated risk area and those in whom viable 
myocardium can be shown to be present with nuclear tech- 
niques (5960) or dobutamine stress echocardiography (61,62) 
might benefit from this procedure. Angioplasty of the infaret- 
related artery a few days before hospital discharge is feasible 
because the vascular occlusion trust be very recent, and is 
probably also safer than angioplasty e lrly after thrombolysis. 
However, a strategy of predischarge angiography with sub- 
sequent revascularisation of severely stenosed or occluded 
infarct-related arteries supplying viable myocardium has not 
been tested yet in a large randomized trial. For this purpose at 
least 308 patients should be randomized to show, with a power 
of 80%, a statistically significant 50% reduction of an expected 
25% reocclusion of very tightly stenosed or occluded infarct 
vessels that are dilated at hospital discharge. As yet, invasive 
strategies in the prevention and treatment of reoczlusion after 
thrombolysis cannot be recommended for routine clinical 
practice. Treatment of Reocclusion 
As stated previously, coronary occlusion is detrimental to 
left ventricular contractile recovery, even in the absence of 
clinical reinfarction. Many believe that once reocclusion is 
diagnosed. thrombolytic therapy for acute myocardial infarc- 
tion has failed. Interestingly, -50% of reocctusions are no1 
accompanied by clinical recurrent infarction or recurrent isch- 
emia (16) and thus are silent. &perfusion therapy with 
angioplasty even weeks after myocardial infarction seems to be 
beneficial in selected patients in terms of left ventricular 
functional recovery (58). Therefore, it seems that myocardial 
viability exists even after the occurrence of reocclusion. If 
silent reocclusion leaves myocardial tissue viable, it could be 
Conclusions 
Reocclusion after thrombolytic therapy for acute myocar- 
dial infarction remains a major problem in everyday cardiol- 
ogy. It is probably thrombotic in origin and its incidence varies 
strongly at the time of diagnosis: from 5% to 30%. The highest 
incidence is seen’ after proven initial occlusion of the infarct- 
related artery. Tht incidence is -5% to 10% during the 
hospital stay for the index infarction and levels off to -30% in 
the first year. Reocclusion interferes with left ventricular 
contractile recovery and also seems to be associated with high 
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morbidity and mortality. It might be predicted by early angiog 
raphy, but so far invasive strategies have f&led to prevent it. 
Whether recxclusion can be prevented by the use of antithrom- 
botic agents is still unclear. Both heparin and aspirin are 
associated with better patency, but randomized, controlled 
trials with these agents in the prevention of angiographically 
oroven reocclusion are small and inconclusive. More anti- 
thrombotic and antiplatekt drugs need to be tested in the 
prevention of reocclusion. 
Because reocclusion is often silent. it is possible that viable 
mvocardium remain? even after reocclusion. Therefore, inva- 
si& !reatmcnt of coronary rcocclusion may he an option in the 
furtht.r improvement o! thrombolytic therapy, but this should 
be tested lint in a randomized trial. Etoth the prevention and 
treatment of retxxlusion after thrombolytic thkrapy are main 
fields of future clinical research. 
16. Ohman EM. Calill RM. Topol EJ, et al Consequences of reocclusion after 
tucceuful reperfusion therapy in acute myocardial infarction. Circulalion 
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